Search

Objectives To examine incidence ofand factors associated with metabolic syndrome in patients with majordepressive disorder within a year. Methods All majordepressive disorder (MDD)patients who visited our psychiatric clinic were screened. All subjects were screenedby the metabolic syndrome criteria proposed by the American Heart Association/National Heart, Lung, and BloodInstitute (updated ATPIII). Subjects who did not meet the criteria of metabolicsyndrome would come after one year to screen for it again. Age and history ofused atypical antipsychotic use, duration of illness, severity of illness andfamily history of metabolic syndrome were assessed as factors associated withthe metabolic syndrome. Data was analyzed by using percentage, mean, standarddeviations, student t-test, chi-square test and Fisher's exact test. Result There were 140 subjectsrecruited. 53 were excluded because they had metabolic syndrome. After one year77 of 87 came to the follow up visit for screening metabolic syndrome. The1-year incidence of metabolic is 16.9%(13 subjects) and 11.7%(9 subjects) dueto ATP III and IDF criteria respectively. Triglyceride and HDL at baseline wassignificantly associated with metabolic syndrome in patients with majordepressive disorder (p≤0.001). Age andhistory of used atypical antipsychotic use, duration of illness, severity ofillness and family history of metabolic were not associated with metabolicsyndrome. Conclusions Thai MDD patients are likely to have and developmetabolic syndrome. These findings support the importance of assessing andmonitoring metabolic syndrome in MDD patients especially in patients who havehigh triglyceride and HDL. [ABSTRACT FROM AUTHOR]

Objectives: [-] To evaluate social function and overall improvement of paliperidone ER treatment in Thai schizophrenia patient. [-] To collect the safety data of Paliperidone ER. Methods: Patients were at least 18 years old and had been diagnosed with schizophrenia according to DSM-IV criteria. Patients were unsatisfied with previous treatment and had been previously or currently on oral atypical antipsychotics. Eligible patients were initiated on a dose of paliperidone ER (3, 6, 9, 12 mg/day) based on tolerability of previous medication. Flexible maintenance dosing during the 10 week study duration was allowed for all participants based on individual tolerability. The primary outcome is social function, determined by Personal and Social Performance Scale (PSP). Patients were also rated for overall severity of illness using Clinical and Global Impressions-Severity (CGI-S) scale. Results: In total, 40 patients were enrolled. The statistical significant improvements from baseline in PSP total score were observed at all time points. An improvement of greater than or equal to 1 category (classified as a10-point interval) on PSP scale is considered as clinical relevant response. Improvement in CGI-S were observed at endpoint (p<0.001). The mean reduction ± SD at endpoint was for 0.8±1.04 (95% CI 0.48-1.16). The most commonly reported adverse events (3 5% of patients) were daytime drowsiness (15%) and headache (15%). Three subjects (7.5%) discontinued due to adverse events. Conclusion: This study suggests that paliperidone ER is well tolerated in schizophrenic patient. Paliperidone ER showed improvement in schizophrenic symptom control and social functioning. [ABSTRACT FROM AUTHOR]

Objective: The purpose of this study was to assess the reliability and validity of the Thai version of the CDSS for the evaluation of depression in patients with schizophrenia. Method: Sixty patients with schizophrenia according to DSM-IV-TR were recruited in the study. The Thai version of CDSS, the Mongomery and Asberg Depression Scale (MADRS), the Hamilton Depression Rating Scale, 17-item version (HDRS-17), and the Positive and Negative Syndrome Scale (PANSS) were administered. Major depressive episode diagnosed by a psychiatrist according to the DSM-IV-TR was used as a gold-standard. Results: The internal consistency of the Thai version of CDSS was very good (Cronbach’s alpha =0.869). The inter-rater reliability was found to be in substantial agreement with the intra-class correlation coefficient (ICC) of 0.979. The test-retest reliability over a period of three days was high, with the ICC of 0.861. The Thai version of CDSS showed significant correlations with the MADRS (r =0.887), the HDRS-17 (r=0.865) and the PANSS-G6 (r=0.833). The areas under the ROC curves of the CDSS, MADRS, HDRS-17, and PANSS-G6 against the DSM-IV-TR criteria for major depressive episode were 0.993, 0.954, 0.966, and 0.933, respectively. The optimal cut-off scores to discriminate between depressed and nondepressed patients was 6/7, with a sensitivity of 92.31% and specificity of 97.87%. Conclusion: The Thai version of CDSS is a reliable and valid measure for the evaluation of depression in Thai patients with schizophrenia. [Copyright &y& Elsevier]